»¶ÀÖ¶·µØÖ÷_Õ©½ð»¨ÓÎÏ·

LI Bing, WANG Jing, LI Jianglin

( Department of General Surgery, the First Affiliated Hospital of Henan 

University,Kaifeng 475000, China)

Abstract Objective To observate the anti-tumor effect of Lentinan combined with Sintilimab in pancreatic cancer and its effect on patient immune response. Methods 95 patients with pancreatic cancer were randomly divided into two groups. 47 cases in the conventional group were treated with Sintilimab. The combined group of 48 cases were treated with Lentinan combined with Sintilimab. Both groups were followed up for 1 year to compare their tumor markers, immune function, recent efficacy, and short-term survival. Results The levels of CEA, CA199, CA242, T cell surface antigen CD3+ , CD4+ in the combined group were higher than those in the conventional group, while CD8+ was lower than that in the conventional group. The differences were statistically significant ( P < 0. 05 ) . The levels of INF-¦Ã, IL-2 and IL-4, objective response rate ( ORR ) and disease control rate ( DCR ) were all higher than those in the conventional group. The differences were statistically significant ( P<0.05) . During the follow-up period, the median progression free survival ( PFS) and median overall survival ( OS) within one year in the combined group were higher than those in the conventional group, and the differences were statistically significant ( P<0.05) . Conclusion Lentinan combined with Sintilimab in the treatment of pancreatic cancer produces more ideal anti-tumor effect by enhancing the immune response of patients, which has positive significance in improving the short-term efficacy and short-term prognosis of patients.

Keywords: pancreatic cancer; xindilizumab; mushroom polysaccharides; immune response

DOI:10.19296/j.cnki.1008-2409.2024-03-012

PDF download:click to download